No Excess Mortality up to 10 Years in Early Stages of Breast Cancer in Women Adherent to Oral Endocrine Therapy: A Probabilistic Graphical Modeling Approach

dc.contributor.authorClèries Soler, Ramon
dc.contributor.authorBuxó, Maria
dc.contributor.authorVilardell, Mireia
dc.contributor.authorAmeijide, Alberto
dc.contributor.authorMartínez, José Miguel
dc.contributor.authorFont, Rebeca
dc.contributor.authorMarcos Gragera, Rafael
dc.contributor.authorPuigdemont, Montserrat
dc.contributor.authorViñas, Gemma
dc.contributor.authorCarulla, Marià
dc.contributor.authorEspinàs Piñol, Josep Alfons
dc.contributor.authorGalceran, Jaume
dc.contributor.authorIzquierdo i Font, Àngel Xavier
dc.contributor.authorBorràs, Josep Maria
dc.date.accessioned2022-04-19T13:21:38Z
dc.date.available2022-04-19T13:21:38Z
dc.date.issued2022-03-18
dc.date.updated2022-04-19T10:50:49Z
dc.description.abstractBreast cancer (BC) is globally the most frequent cancer in women. Adherence to endocrine therapy (ET) in hormone-receptor-positive BC patients is active and voluntary for the first five years after diagnosis. This study examines the impact of adherence to ET on 10-year excess mortality (EM) in patients diagnosed with Stages I to III BC (N = 2297). Since sample size is an issue for estimating age- and stage-specific survival indicators, we developed a method, ComSynSurData, for generating a large synthetic dataset (SynD) through probabilistic graphical modeling of the original cohort. We derived population-based survival indicators using a Bayesian relative survival model fitted to the SynD. Our modeling showed that hormone-receptor-positive BC patients diagnosed beyond 49 years of age at Stage I or beyond 59 years at Stage II do not have 10-year EM if they follow the prescribed ET regimen. This result calls for developing interventions to promote adherence to ET in patients with hormone receptor-positive BC and in turn improving cancer survival. The presented methodology here demonstrates the potential use of probabilistic graphical modeling for generating reliable synthetic datasets for validating population-based survival indicators when sample size is an issue.
dc.format.extent17 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec723021
dc.identifier.issn1660-4601
dc.identifier.pmid35329292
dc.identifier.urihttps://hdl.handle.net/2445/185037
dc.language.isoeng
dc.publisherMDPI AG
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/ijerph19063605
dc.relation.ispartofInternational Journal of Environmental Research and Public Health, 2022, vol. 19, num. 6
dc.relation.urihttps://doi.org/10.3390/ijerph19063605
dc.rightscc by (c) Clèries Soler, Ramon et al, 2022
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
dc.subject.classificationCàncer de mama
dc.subject.classificationEndocrinologia
dc.subject.otherBreast cancer
dc.subject.otherEndocrinology
dc.titleNo Excess Mortality up to 10 Years in Early Stages of Breast Cancer in Women Adherent to Oral Endocrine Therapy: A Probabilistic Graphical Modeling Approach
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
ijerph-19-03605.pdf
Mida:
1.88 MB
Format:
Adobe Portable Document Format